News | Structural Heart Occluders | March 27, 2019

SCAI Offers Recommendations for Safe Use of PFO Closure Technologies

Completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone 

SCAI Offers Recommendations for Safe Use of PFO Closure Technologies. SCAI said completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective dissemination of newly approved patent foramen ovale (PFO) closure technologies. The document, developed by the Society for Cardiovascular Angiography and Interventions (SCAI) and affirmed by the American Academy of Neurology (AAN), was published online in SCAI’s official journal, Catheterization and Cardiovascular Interventions.

Access the full text of the "SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke.[1]

Nearly 25 percent of the general population may have a PFO, which is an opening between the top left and right chambers of the heart. Closure of the PFO is one strategy in mitigating the risk of recurrent stroke in PFO patients who have experienced a cryptogenic stroke. Stroke is the fifth most common cause of death and the leading cause of preventable disability in the United States.

“Completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone for appropriately selected patients with cryptogenic stroke and a PFO was a landmark achievement that has resolved decades of uncertainty,” said Eric Horlick, M.D., FSCAI, chair of the paper’s writing group and an interventional cardiologist at the Peter Munk Cardiac Centre, University of Toronto.

The writing group makes specific recommendations in the paper for operator competencies and training, facility infrastructure, multidisciplinary collaboration, and quality assessment measures. “The appropriate use of PFO closure has the potential to change the natural history of a potentially devastating disease process. SCAI and AAN representatives collaborated to help cardiologists and neurologists provide the highest standard of care,” Horlick said.

“SCAI can now confidently offer evidenced-based recommendations for the treatment of these patients, who are seeking answers to guide their therapeutic decision making after a potentially catastrophic event. I am very proud of the work produced by our dedicated and highly experienced SCAI writing group, including representatives from the AAN. The resulting document is pragmatic and aims to inform and assist clinicians and institutions in maintaining an evidenced-based, patient-centered approach to the care of this patient population with a focus on quality and safety.,” he continued.

The U.S. Food and Drug Administration (FDA) recently approved two percutaneous PFO occluder devices. Prior to approval, closure devices had only been available off-label through a humanitarian device exemption, and in randomized clinical trials. Now approved, the devices are widely available.

 

Related PFO Closure Content:

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — Interview with John Rhodes, M.D.

VIDEO: An Overview of PFO Closure to Treat Cryptogenic Stroke — Interview with Karen Orjuela, M.D.

VIDEO: Transcatheter Closure of Holes in the Heart — Interview with Ziyad Hijazi, M.D.

VIDEO: Demonstration of a Transcatheter PFO Occluder Implantation

VIDEO: Addressing Adult Congenital Heart Referrals — Interview with Ami Bhatt, M.D.

 

Reference:

1. Eric Horlick, Clifford J. Kavinsky, Zahid Amin, et al. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke. Catheterization and Cardiovascular Interventions. First published online 21 March 2019. https://doi.org/10.1002/ccd.28111

 

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Overlay Init